JP7581264B2 - 細胞および組織への薬剤の送達のための新規ペプチド、組成物および方法 - Google Patents
細胞および組織への薬剤の送達のための新規ペプチド、組成物および方法 Download PDFInfo
- Publication number
- JP7581264B2 JP7581264B2 JP2021578241A JP2021578241A JP7581264B2 JP 7581264 B2 JP7581264 B2 JP 7581264B2 JP 2021578241 A JP2021578241 A JP 2021578241A JP 2021578241 A JP2021578241 A JP 2021578241A JP 7581264 B2 JP7581264 B2 JP 7581264B2
- Authority
- JP
- Japan
- Prior art keywords
- aav
- peptide
- cell
- nuc1
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 157
- 239000003814 drug Substances 0.000 title claims description 83
- 238000000034 method Methods 0.000 title claims description 61
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 54
- 229940079593 drug Drugs 0.000 title description 59
- 239000000203 mixture Substances 0.000 title description 11
- 108090000738 Decorin Proteins 0.000 claims description 161
- 102000004237 Decorin Human genes 0.000 claims description 161
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims description 53
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims description 53
- 241000700605 Viruses Species 0.000 claims description 53
- 239000003795 chemical substances by application Substances 0.000 claims description 48
- 230000006378 damage Effects 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 28
- 102000050257 X-Linked Inhibitor of Apoptosis Human genes 0.000 claims description 23
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 23
- 108091033319 polynucleotide Proteins 0.000 claims description 20
- 102000040430 polynucleotide Human genes 0.000 claims description 20
- 239000002157 polynucleotide Substances 0.000 claims description 20
- 208000027418 Wounds and injury Diseases 0.000 claims description 19
- 238000001415 gene therapy Methods 0.000 claims description 18
- 208000014674 injury Diseases 0.000 claims description 18
- 101710136259 E3 ubiquitin-protein ligase XIAP Proteins 0.000 claims description 17
- 238000010362 genome editing Methods 0.000 claims description 17
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 16
- 230000003612 virological effect Effects 0.000 claims description 16
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 14
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 14
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 150000007523 nucleic acids Chemical class 0.000 claims description 14
- 229920001184 polypeptide Polymers 0.000 claims description 14
- 108091033409 CRISPR Proteins 0.000 claims description 13
- 230000001965 increasing effect Effects 0.000 claims description 13
- 108090000565 Capsid Proteins Proteins 0.000 claims description 11
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 11
- 230000003510 anti-fibrotic effect Effects 0.000 claims description 10
- 229960003957 dexamethasone Drugs 0.000 claims description 10
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 150000003431 steroids Chemical class 0.000 claims description 9
- 239000013598 vector Substances 0.000 claims description 8
- 208000020564 Eye injury Diseases 0.000 claims description 7
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 7
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 7
- 102000004389 Ribonucleoproteins Human genes 0.000 claims description 7
- 108010081734 Ribonucleoproteins Proteins 0.000 claims description 7
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 7
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 241000702421 Dependoparvovirus Species 0.000 claims description 6
- 230000002424 anti-apoptotic effect Effects 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 150000003384 small molecules Chemical class 0.000 claims description 6
- 238000010361 transduction Methods 0.000 claims description 6
- 230000026683 transduction Effects 0.000 claims description 6
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 5
- 230000003412 degenerative effect Effects 0.000 claims description 5
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 claims description 4
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 claims description 4
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 claims description 4
- 102000016611 Proteoglycans Human genes 0.000 claims description 4
- 108010067787 Proteoglycans Proteins 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 208000030533 eye disease Diseases 0.000 claims 4
- 101150015886 nuc-1 gene Proteins 0.000 description 226
- 210000004027 cell Anatomy 0.000 description 174
- 210000004087 cornea Anatomy 0.000 description 124
- 241000699670 Mus sp. Species 0.000 description 102
- 210000001525 retina Anatomy 0.000 description 101
- 239000003513 alkali Substances 0.000 description 86
- 210000001519 tissue Anatomy 0.000 description 77
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 66
- 239000002953 phosphate buffered saline Substances 0.000 description 66
- 238000011282 treatment Methods 0.000 description 66
- 238000010186 staining Methods 0.000 description 62
- 108090000623 proteins and genes Proteins 0.000 description 58
- 230000002207 retinal effect Effects 0.000 description 58
- 210000001508 eye Anatomy 0.000 description 54
- 230000014509 gene expression Effects 0.000 description 51
- 239000007924 injection Substances 0.000 description 50
- 238000002347 injection Methods 0.000 description 50
- 235000018102 proteins Nutrition 0.000 description 45
- 102000004169 proteins and genes Human genes 0.000 description 45
- 230000000699 topical effect Effects 0.000 description 38
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 30
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 30
- 206010016654 Fibrosis Diseases 0.000 description 30
- 230000004761 fibrosis Effects 0.000 description 30
- 208000015181 infectious disease Diseases 0.000 description 28
- 230000009467 reduction Effects 0.000 description 27
- 208000003098 Ganglion Cysts Diseases 0.000 description 25
- 208000005400 Synovial Cyst Diseases 0.000 description 25
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 230000006907 apoptotic process Effects 0.000 description 23
- 108090001090 Lectins Proteins 0.000 description 19
- 102000004856 Lectins Human genes 0.000 description 19
- 210000000981 epithelium Anatomy 0.000 description 18
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- ZRKWMRDKSOPRRS-UHFFFAOYSA-N N-Methyl-N-nitrosourea Chemical compound O=NN(C)C(N)=O ZRKWMRDKSOPRRS-UHFFFAOYSA-N 0.000 description 17
- 210000000234 capsid Anatomy 0.000 description 17
- 230000002829 reductive effect Effects 0.000 description 17
- 206010061218 Inflammation Diseases 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 16
- 102000007469 Actins Human genes 0.000 description 15
- 108010085238 Actins Proteins 0.000 description 15
- 108010051219 Cre recombinase Proteins 0.000 description 15
- 230000004054 inflammatory process Effects 0.000 description 15
- 230000035515 penetration Effects 0.000 description 15
- 238000011002 quantification Methods 0.000 description 15
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 14
- 102000003952 Caspase 3 Human genes 0.000 description 14
- 108090000397 Caspase 3 Proteins 0.000 description 14
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 14
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 14
- 229920002971 Heparan sulfate Polymers 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 14
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 14
- 108700019146 Transgenes Proteins 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 108091008695 photoreceptors Proteins 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 12
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 12
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 12
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 12
- 210000004940 nucleus Anatomy 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 230000008685 targeting Effects 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 238000013042 tunel staining Methods 0.000 description 12
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 11
- 102000003923 Protein Kinase C Human genes 0.000 description 11
- 108090000315 Protein Kinase C Proteins 0.000 description 11
- 210000000170 cell membrane Anatomy 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 208000002780 macular degeneration Diseases 0.000 description 11
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 10
- 206010038848 Retinal detachment Diseases 0.000 description 10
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 10
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 10
- 206010064930 age-related macular degeneration Diseases 0.000 description 10
- -1 antibodies Proteins 0.000 description 10
- 210000003683 corneal stroma Anatomy 0.000 description 10
- 108010054624 red fluorescent protein Proteins 0.000 description 10
- 230000004264 retinal detachment Effects 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- 206010029113 Neovascularisation Diseases 0.000 description 9
- 230000030833 cell death Effects 0.000 description 9
- 230000008595 infiltration Effects 0.000 description 9
- 238000001764 infiltration Methods 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 206010018341 Gliosis Diseases 0.000 description 8
- 108010074328 Interferon-gamma Proteins 0.000 description 8
- 102000008070 Interferon-gamma Human genes 0.000 description 8
- 102000004889 Interleukin-6 Human genes 0.000 description 8
- 108090001005 Interleukin-6 Proteins 0.000 description 8
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 8
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 230000033115 angiogenesis Effects 0.000 description 8
- 230000021615 conjugation Effects 0.000 description 8
- 230000007387 gliosis Effects 0.000 description 8
- 102000005396 glutamine synthetase Human genes 0.000 description 8
- 108020002326 glutamine synthetase Proteins 0.000 description 8
- 229960003130 interferon gamma Drugs 0.000 description 8
- 108010057670 laminin 1 Proteins 0.000 description 8
- 238000010172 mouse model Methods 0.000 description 8
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 8
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 7
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 7
- 239000013543 active substance Substances 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 230000036542 oxidative stress Effects 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 239000013603 viral vector Substances 0.000 description 7
- 108010003730 Cone Opsins Proteins 0.000 description 6
- 208000006069 Corneal Opacity Diseases 0.000 description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 6
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 6
- 208000010412 Glaucoma Diseases 0.000 description 6
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- 208000022873 Ocular disease Diseases 0.000 description 6
- 229930040373 Paraformaldehyde Natural products 0.000 description 6
- 201000007737 Retinal degeneration Diseases 0.000 description 6
- 102000005801 Rod Opsins Human genes 0.000 description 6
- 108010005063 Rod Opsins Proteins 0.000 description 6
- 102000004243 Tubulin Human genes 0.000 description 6
- 108090000704 Tubulin Proteins 0.000 description 6
- 108700031544 X-Linked Inhibitor of Apoptosis Proteins 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 210000003038 endothelium Anatomy 0.000 description 6
- 210000000871 endothelium corneal Anatomy 0.000 description 6
- 210000002744 extracellular matrix Anatomy 0.000 description 6
- 229920002866 paraformaldehyde Polymers 0.000 description 6
- 230000000770 proinflammatory effect Effects 0.000 description 6
- 238000011200 topical administration Methods 0.000 description 6
- 201000004569 Blindness Diseases 0.000 description 5
- 208000028006 Corneal injury Diseases 0.000 description 5
- 102000013691 Interleukin-17 Human genes 0.000 description 5
- 108050003558 Interleukin-17 Proteins 0.000 description 5
- 102100021010 Nucleolin Human genes 0.000 description 5
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 210000001742 aqueous humor Anatomy 0.000 description 5
- 230000004888 barrier function Effects 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 210000003855 cell nucleus Anatomy 0.000 description 5
- 210000003161 choroid Anatomy 0.000 description 5
- 231100000269 corneal opacity Toxicity 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 5
- 238000010348 incorporation Methods 0.000 description 5
- 239000007928 intraperitoneal injection Substances 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 108010044762 nucleolin Proteins 0.000 description 5
- 238000010647 peptide synthesis reaction Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 102000015696 Interleukins Human genes 0.000 description 4
- 108010063738 Interleukins Proteins 0.000 description 4
- 108010085895 Laminin Proteins 0.000 description 4
- 102000007547 Laminin Human genes 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 206010046851 Uveitis Diseases 0.000 description 4
- 108010081667 aflibercept Proteins 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000002469 basement membrane Anatomy 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000000942 confocal micrograph Methods 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 210000003560 epithelium corneal Anatomy 0.000 description 4
- 229940051306 eylea Drugs 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 238000002073 fluorescence micrograph Methods 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 210000004969 inflammatory cell Anatomy 0.000 description 4
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 4
- 210000000554 iris Anatomy 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 210000000651 myofibroblast Anatomy 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 210000001747 pupil Anatomy 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000004258 retinal degeneration Effects 0.000 description 4
- 230000037390 scarring Effects 0.000 description 4
- 210000002460 smooth muscle Anatomy 0.000 description 4
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- BQENDLAVTKRQMS-SBBGFIFASA-L Carbenoxolone sodium Chemical compound [Na+].[Na+].C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)CCC([O-])=O)C1(C)C BQENDLAVTKRQMS-SBBGFIFASA-L 0.000 description 3
- 208000002177 Cataract Diseases 0.000 description 3
- 208000009043 Chemical Burns Diseases 0.000 description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 3
- 102000003814 Interleukin-10 Human genes 0.000 description 3
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- 102000011782 Keratins Human genes 0.000 description 3
- 108010076876 Keratins Proteins 0.000 description 3
- 241000700584 Simplexvirus Species 0.000 description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- 108090000054 Syndecan-2 Proteins 0.000 description 3
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000021164 cell adhesion Effects 0.000 description 3
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 229960004359 iodixanol Drugs 0.000 description 3
- 206010023332 keratitis Diseases 0.000 description 3
- 230000009437 off-target effect Effects 0.000 description 3
- 210000001328 optic nerve Anatomy 0.000 description 3
- 230000000149 penetrating effect Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 230000004393 visual impairment Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- BFUUJUGQJUTPAF-UHFFFAOYSA-N 2-(3-amino-4-propoxybenzoyl)oxyethyl-diethylazanium;chloride Chemical compound [Cl-].CCCOC1=CC=C(C(=O)OCC[NH+](CC)CC)C=C1N BFUUJUGQJUTPAF-UHFFFAOYSA-N 0.000 description 2
- 239000013607 AAV vector Substances 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 108700032225 Antioxidant Response Elements Proteins 0.000 description 2
- 229940088872 Apoptosis inhibitor Drugs 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 208000018380 Chemical injury Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 2
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010016101 Griffonia simplicifolia lectins Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001000206 Homo sapiens Decorin Proteins 0.000 description 2
- 101000804865 Homo sapiens E3 ubiquitin-protein ligase XIAP Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 210000005156 Müller Glia Anatomy 0.000 description 2
- 208000021957 Ocular injury Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 208000002367 Retinal Perforations Diseases 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 238000012288 TUNEL assay Methods 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229960002833 aflibercept Drugs 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000001772 anti-angiogenic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000000158 apoptosis inhibitor Substances 0.000 description 2
- 229940120638 avastin Drugs 0.000 description 2
- 238000002869 basic local alignment search tool Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000004397 blinking Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 201000000159 corneal neovascularization Diseases 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000004406 elevated intraocular pressure Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 230000004914 glial activation Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 229940089982 healon Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 102000052732 human XIAP Human genes 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000013532 laser treatment Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000037125 natural defense Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000649 photocoagulation Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 231100000683 possible toxicity Toxicity 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 229960001371 proparacaine hydrochloride Drugs 0.000 description 2
- 229960003876 ranibizumab Drugs 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 210000000964 retinal cone photoreceptor cell Anatomy 0.000 description 2
- 210000003994 retinal ganglion cell Anatomy 0.000 description 2
- 239000000790 retinal pigment Substances 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000036573 scar formation Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 229940126586 small molecule drug Drugs 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 210000001585 trabecular meshwork Anatomy 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 230000034512 ubiquitination Effects 0.000 description 2
- 238000010798 ubiquitination Methods 0.000 description 2
- 238000011870 unpaired t-test Methods 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- PJDINCOFOROBQW-LURJTMIESA-N (3S)-3,7-diaminoheptanoic acid Chemical compound NCCCC[C@H](N)CC(O)=O PJDINCOFOROBQW-LURJTMIESA-N 0.000 description 1
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- CDKIEBFIMCSCBB-UHFFFAOYSA-N 1-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one;hydrochloride Chemical compound Cl.C1C=2C=C(OC)C(OC)=CC=2CCN1C(=O)C=CC(C1=CC=CN=C1N1C)=C1C1=CC=CC=C1 CDKIEBFIMCSCBB-UHFFFAOYSA-N 0.000 description 1
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 1
- YIYCUMYWGOOSNU-FMZZOXHWSA-N 2-[[(2s)-1-[(2s,3s)-2-[[(2s,3r)-2-[[2-[[(2s)-2-amino-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]acetic acid Chemical group CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O YIYCUMYWGOOSNU-FMZZOXHWSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000649044 Adeno-associated virus 9 Species 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 108700031308 Antennapedia Homeodomain Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 108091016585 CD44 antigen Proteins 0.000 description 1
- 102100029968 Calreticulin Human genes 0.000 description 1
- 108090000549 Calreticulin Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010719 Conjunctival haemorrhage Diseases 0.000 description 1
- 206010010984 Corneal abrasion Diseases 0.000 description 1
- 206010055665 Corneal neovascularisation Diseases 0.000 description 1
- 206010071164 Corneal thickening Diseases 0.000 description 1
- 102100028908 Cullin-3 Human genes 0.000 description 1
- 101710094482 Cullin-3 Proteins 0.000 description 1
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 description 1
- 238000000116 DAPI staining Methods 0.000 description 1
- 102100035784 Decorin Human genes 0.000 description 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 208000001351 Epiretinal Membrane Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000030306 Eye degenerative disease Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 208000024412 Friedreich ataxia Diseases 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 241000219774 Griffonia Species 0.000 description 1
- 241000219726 Griffonia simplicifolia Species 0.000 description 1
- 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 208000031354 Hyphema Diseases 0.000 description 1
- 206010065042 Immune reconstitution inflammatory syndrome Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
- 201000002287 Keratoconus Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000031471 Macular fibrosis Diseases 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 1
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 1
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 1
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 101100398282 Mus musculus Kit gene Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000019462 Occupational injury Diseases 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 108010088535 Pep-1 peptide Proteins 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 1
- 101710149951 Protein Tat Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 108090000820 Rhodopsin Proteins 0.000 description 1
- 102100040756 Rhodopsin Human genes 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000001732 Small Leucine-Rich Proteoglycans Human genes 0.000 description 1
- 108010040068 Small Leucine-Rich Proteoglycans Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010065647 Systemic leakage Diseases 0.000 description 1
- 240000004584 Tamarindus indica Species 0.000 description 1
- 235000004298 Tamarindus indica Nutrition 0.000 description 1
- 101710192266 Tegument protein VP22 Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- 208000014769 Usher Syndromes Diseases 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004155 blood-retinal barrier Anatomy 0.000 description 1
- 230000004378 blood-retinal barrier Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000014564 chemokine production Effects 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002442 collagenase inhibitor Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000000882 contact lens solution Substances 0.000 description 1
- 210000003239 corneal fibroblast Anatomy 0.000 description 1
- 230000004453 corneal transparency Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 208000001763 cytomegalovirus retinitis Diseases 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 201000011190 diabetic macular edema Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 208000001936 exophthalmos Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 102000045840 human DCN Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000008798 inflammatory stress Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 description 1
- 210000001153 interneuron Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 208000029233 macular holes Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000008397 ocular pathology Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000003733 optic disk Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 108010043655 penetratin Proteins 0.000 description 1
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 description 1
- 229950006286 pentrinitrol Drugs 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 210000000608 photoreceptor cell Anatomy 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 108010094020 polyglycine Proteins 0.000 description 1
- 229920000232 polyglycine polymer Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000009163 protein therapy Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000001116 retinal neuron Anatomy 0.000 description 1
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
- 210000000880 retinal rod photoreceptor cell Anatomy 0.000 description 1
- 239000012487 rinsing solution Substances 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000008625 synaptic signaling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000025366 tissue development Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 108010062760 transportan Proteins 0.000 description 1
- PBKWZFANFUTEPS-CWUSWOHSSA-N transportan Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(N)=O)[C@@H](C)CC)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CC=C(O)C=C1 PBKWZFANFUTEPS-CWUSWOHSSA-N 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/49—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962869831P | 2019-07-02 | 2019-07-02 | |
| US62/869,831 | 2019-07-02 | ||
| PCT/US2020/040720 WO2021034418A2 (en) | 2019-07-02 | 2020-07-02 | Novel peptide, compositions and method for delivery of agents into cells and tissues |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022538903A JP2022538903A (ja) | 2022-09-06 |
| JP2022538903A5 JP2022538903A5 (https=) | 2023-07-11 |
| JPWO2021034418A5 JPWO2021034418A5 (https=) | 2023-07-11 |
| JP7581264B2 true JP7581264B2 (ja) | 2024-11-12 |
Family
ID=74659924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021578241A Active JP7581264B2 (ja) | 2019-07-02 | 2020-07-02 | 細胞および組織への薬剤の送達のための新規ペプチド、組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11713337B2 (https=) |
| EP (1) | EP3994151A4 (https=) |
| JP (1) | JP7581264B2 (https=) |
| KR (1) | KR20220039725A (https=) |
| CN (1) | CN114555625B (https=) |
| AU (1) | AU2020332268B2 (https=) |
| CA (1) | CA3144963A1 (https=) |
| IL (1) | IL289516A (https=) |
| WO (1) | WO2021034418A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3100276A1 (en) | 2018-06-06 | 2019-12-12 | Massachusetts Institute Of Technology | Circular rna for translation in eukaryotic cells |
| WO2026005189A1 (ko) * | 2024-06-27 | 2026-01-02 | 이엔셀 주식회사 | 안구 세포 또는 조직을 표적하는 펩타이드 및 이를 포함하는 바이러스 캡시드 단백질 및 바이러스 벡터 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002518050A (ja) | 1998-06-19 | 2002-06-25 | メディジーン・アクチェンゲゼルシャフト | Ａａｖの構造タンパク質、その製造及び用途 |
| JP2007531691A (ja) | 2003-05-19 | 2007-11-08 | デルマゲン アクティエボラーグ | ヘパリン結合活性を有する新規な抗微生物ペプチド |
| JP2012530787A (ja) | 2009-06-22 | 2012-12-06 | バーナム インスティテュート フォー メディカル リサーチ | Ｃ末端エレメントを有するペプチドおよびタンパク質を使用する方法および組成物 |
| US20130158103A1 (en) | 2011-11-23 | 2013-06-20 | The Curators Of The University Of Missouri | Method of Tissue-Selective Targeted Gene Transfer |
| WO2016143828A1 (ja) | 2015-03-12 | 2016-09-15 | 三洋化成工業株式会社 | タンパク質組成物の製造方法及びタンパク質組成物 |
| US20170349628A1 (en) | 2014-10-02 | 2017-12-07 | Temple University-Of The Commonwealth System Of Higher Education | Synthesis of Cell Penetrating Peptides for Drug Delivery and Stem Cell Applications |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5211657A (en) * | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
| US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
| JP3635462B2 (ja) * | 2000-05-31 | 2005-04-06 | 国立医薬品食品衛生研究所長 | アデノウイルスベクター |
| US8076295B2 (en) * | 2007-04-17 | 2011-12-13 | Nanotope, Inc. | Peptide amphiphiles having improved solubility and methods of using same |
| AU2008295509A1 (en) * | 2007-08-29 | 2009-03-12 | Tufts University | Methods of making and using a cell penetrating peptide for enhanced delivery of nucleic acids, proteins, drugs, and adenovirus to tissues and cells, and compositions and kits |
| EP2187907A2 (en) * | 2007-09-11 | 2010-05-26 | Mondobiotech Laboratories AG | Use of tyr-w-mif-1 and urocortin 2 as therapeutic agents |
| EP3076792B1 (en) * | 2013-12-04 | 2020-11-11 | Newleaf Symbiotics, Inc. | Compositions and methods for improving lettuce production |
| US9738687B2 (en) * | 2015-04-10 | 2017-08-22 | Feldan Bio Inc. | Polypeptide-based shuttle agents for improving the transduction efficiency of polypeptide cargos to the cytosol of target eukaryotic cells, uses thereof, methods and kits relating to same |
-
2020
- 2020-07-02 JP JP2021578241A patent/JP7581264B2/ja active Active
- 2020-07-02 CA CA3144963A patent/CA3144963A1/en active Pending
- 2020-07-02 EP EP20854383.5A patent/EP3994151A4/en active Pending
- 2020-07-02 CN CN202080055898.6A patent/CN114555625B/zh active Active
- 2020-07-02 KR KR1020227003440A patent/KR20220039725A/ko active Pending
- 2020-07-02 WO PCT/US2020/040720 patent/WO2021034418A2/en not_active Ceased
- 2020-07-02 AU AU2020332268A patent/AU2020332268B2/en not_active Expired - Fee Related
-
2021
- 2021-12-30 IL IL289516A patent/IL289516A/en unknown
- 2021-12-30 US US17/646,496 patent/US11713337B2/en active Active
-
2023
- 2023-06-08 US US18/331,851 patent/US20230340024A1/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002518050A (ja) | 1998-06-19 | 2002-06-25 | メディジーン・アクチェンゲゼルシャフト | Ａａｖの構造タンパク質、その製造及び用途 |
| JP2007531691A (ja) | 2003-05-19 | 2007-11-08 | デルマゲン アクティエボラーグ | ヘパリン結合活性を有する新規な抗微生物ペプチド |
| JP2012530787A (ja) | 2009-06-22 | 2012-12-06 | バーナム インスティテュート フォー メディカル リサーチ | Ｃ末端エレメントを有するペプチドおよびタンパク質を使用する方法および組成物 |
| US20130158103A1 (en) | 2011-11-23 | 2013-06-20 | The Curators Of The University Of Missouri | Method of Tissue-Selective Targeted Gene Transfer |
| US20170349628A1 (en) | 2014-10-02 | 2017-12-07 | Temple University-Of The Commonwealth System Of Higher Education | Synthesis of Cell Penetrating Peptides for Drug Delivery and Stem Cell Applications |
| WO2016143828A1 (ja) | 2015-03-12 | 2016-09-15 | 三洋化成工業株式会社 | タンパク質組成物の製造方法及びタンパク質組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20230340024A1 (en) | 2023-10-26 |
| AU2020332268A1 (en) | 2022-02-24 |
| KR20220039725A (ko) | 2022-03-29 |
| CN114555625A (zh) | 2022-05-27 |
| WO2021034418A2 (en) | 2021-02-25 |
| CN114555625B (zh) | 2025-02-25 |
| JP2022538903A (ja) | 2022-09-06 |
| WO2021034418A3 (en) | 2021-04-01 |
| AU2020332268B2 (en) | 2025-04-24 |
| US11713337B2 (en) | 2023-08-01 |
| EP3994151A2 (en) | 2022-05-11 |
| IL289516A (en) | 2022-03-01 |
| EP3994151A4 (en) | 2023-07-19 |
| US20220204562A1 (en) | 2022-06-30 |
| CA3144963A1 (en) | 2021-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8778886B2 (en) | Methods of making and using a cell penetrating peptide for enhanced delivery of nucleic acids, proteins, drugs, and adenovirus to tissues and cells, and compositions and kits | |
| US20250221936A1 (en) | Engineered hemichannels, engineered vesicles, and uses thereof | |
| JP5643237B2 (ja) | 光受容細胞のアポトーシスを抑制する方法 | |
| BR112021007221A2 (pt) | proteínas inteínas e seus usos | |
| JP2021054824A (ja) | 設計されたメガヌクレアーゼを使用した網膜色素変性症の治療 | |
| US20230340024A1 (en) | Novel peptide, compositions and method for delivery of agents into cells and tissues | |
| Liu et al. | siRNA silencing of gene expression in trabecular meshwork: RhoA siRNA reduces IOP in mice | |
| Biswal et al. | Cell-specific gene therapy driven by an optimized hypoxia-regulated vector reduces choroidal neovascularization | |
| Kumar et al. | Cell-Penetrating chaperone Nuc1 for Small-and Large-Molecule delivery into retinal cells and tissues | |
| US20160144055A1 (en) | Gene therapy vector for treatment of steroid glaucoma | |
| Parsons et al. | Regulatable complement inhibition of the alternative pathway mitigates wet age-related macular degeneration pathology in a mouse model | |
| Wu et al. | Tropism and retinal transduction efficiency of adeno-associated virus serotypes in mice | |
| AU2017296189A1 (en) | Ocular delivery of cell permeant therapeutics for the treatment of retinal edema | |
| EA048046B1 (ru) | Новый пептид, композиции и способ доставки агентов в клетки и ткани | |
| US20230190869A1 (en) | Peptide inhibitors of guanine nucleotide exchange factor h-1 | |
| US20250177573A1 (en) | Materials & Methods for Treatment of Macular Degeneration | |
| CN121154789A (zh) | 近视治疗方法 | |
| Read | Non-Viral Gene Therapy for the Treatment of Retinal Degeneration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230629 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230629 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240530 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240829 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240930 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20241030 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7581264 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |